Form 4: 180 Life Sciences CEO Blair Jordan Reports Changes in Beneficial Ownership Due to Voting Agreements
SEC Form 4 Filing
Blair Jordan, CEO of 180 Life Sciences Corp., reports changes in beneficial ownership due to voting agreements with multiple parties, granting him irrevocable voting proxies over their shares.
Summary
- Blair Jordan, CEO of 180 Life Sciences Corp., filed a Form 4 on April 30, 2025, reporting changes in his beneficial ownership of the company's common stock.
- The changes are due to voting agreements with Dr. James Woody (43,166 shares), Dr. Marlene Krauss (200,000 shares), and Elray Resources, Inc. (1,318,000 shares).
- These agreements grant Jordan irrevocable voting proxies to vote these shares as recommended by the Board of Directors until February 5, 2026 (Woody), August 21, 2025 (Krauss), and April 28, 2026 (Elray).
- Jordan does not have dispositive control or any pecuniary interest in these shares, only the right to vote them.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. The voting agreements could be seen as slightly positive for management control, but also carry potential governance risks.
Positives
- The voting agreements consolidate voting power with the CEO, potentially streamlining decision-making and aligning shareholder votes with the board's recommendations.
Risks
- While Jordan doesn't have direct control or financial interest in the shares, the concentration of voting power could raise concerns about corporate governance if not managed transparently.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's financial performance or future prospects, focusing instead on changes in beneficial ownership due to voting agreements.
Industry Context
Voting agreements are a relatively common mechanism used in corporate governance to consolidate voting power, particularly in smaller companies or those undergoing significant transitions. This allows management to ensure that key initiatives are supported by a sufficient number of votes.
Stakeholder Impact
- Shareholders may be impacted by the consolidated voting power, potentially leading to more predictable voting outcomes on company matters.
Key Dates
| Date | Description |
|---|---|
| 02/05/2025 | Voting Agreement between 180 Life Sciences, Blair Jordan, and Dr. James Woody. |
| 02/21/2025 | Voting Agreement between 180 Life Sciences, Blair Jordan, and Dr. Marlene Krauss. |
| 04/28/2025 | Voting Agreement between 180 Life Sciences, Blair Jordan, and Elray Resources, Inc. |
| 04/28/2025 | Date of Earliest Transaction |
| 04/30/2025 | Date of Form 4 Filing |
| 08/05/2025 | Date after which Dr. Woody may have sold all shares. |
| 08/21/2025 | Termination date of the Voting Agreement with Dr. Marlene Krauss. |
| 02/05/2026 | Termination date of the Voting Agreement with Dr. James Woody. |
| 04/28/2026 | Termination date of the Voting Agreement with Elray Resources, Inc. |
Keywords
beneficial ownership, Form 4, voting agreement, proxy, 180 Life Sciences, Blair Jordan, ATNF
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.